Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editor's pick

13-11-2019 | Axial spondyloarthritis | ACR/ARP 2019 | News

Secukinumab may represent a treatment option for nonradiographic axSpA

The PREVENT investigators have reported positive results for the IL-17A inhibitor secukinumab in patients with nonradiographic axial spondyloarthritis at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA.

12-11-2019 | Psoriatic arthritis | ACR/ARP 2019 | News

Guselkumab shows promise for PsA

Findings from the DISCOVER-1 and DISCOVER-2 trials suggest that the interleukin-23 inhibitor guselkumab may be a promising treatment option for people with psoriatic arthritis.

13-11-2019 | Rheumatoid arthritis | ACR/ARP 2019 | News

Methotrexate plus glucocorticoids compare favorably with biologics in early RA

Study findings pitting methotrexate plus glucocorticoid treatment against methotrexate plus one of three biologics in early rheumatoid arthritis provide support for the active conventional treatment.

2019 ACR/ARP Annual Meeting Highlights

Including news and expert commentaries on the NORDSTAR, RITAZAREM and SELECT-AXIS 1 trials.

Latest from across the site

21-11-2019 | Ankylosing spondylitis | News

axSpA management needs to look beyond disease activity and function

To improve the quality of life of patients with ankylosing spondylitis, research suggests that fatigue, poor sleep, and mental health need to be addressed in addition to managing disease activity and function.

21-11-2019 | Rheumatoid arthritis | News

RA comorbidities signal a need to screen

US researchers have identified a number of chronic conditions associated with rheumatoid arthritis, including some that may predispose to RA development and others that may arise as a result of RA.

20-11-2019 | Rheumatoid arthritis | News

Insufficient diversity in RA clinical trial populations

A systematic review has identified insufficient representation of people from racial minority groups, older individuals, and men in randomized controlled trials investigating treatments for rheumatoid arthritis.

19-11-2019 | Rheumatoid arthritis | ACR/ARP 2019 | News

Omega-3 supplements may benefit in RA patients

Taking omega-3 is associated with a reduction in measures of rheumatoid arthritis disease activity, suggests real-world data.

18-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | Article

No benefit of add-on fenebrutinib for patients with SLE

Addition of the Bruton’s tyrosine kinase inhibitor fenebrutinib to standard care does not improve outcomes for patients with systemic lupus erythematosus, suggest findings from a phase II trial.

15-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | News

Further investigation of telitacicept may be warranted for SLE

Telitacicept, a recombinant fusion protein targeting B-lymphocyte stimulator and the APRIL proliferation-inducing ligand, has shown potential for the treatment of systemic lupus erythematosus in a phase IIb trial conducted in China.

Latest from us on Twitter

Trending this week

Meet our Editorial Board

New Content Item Meet our Advisory Board

Image Credits